Home > Boards > US OTC > Miscellaneous > Kannalife Inc. (KLFE)

Nice news ! $KLFE

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
resx18 Member Profile
Member Level 
Followed By 362
Posts 18,248
Boards Moderated 11
Alias Born 02/28/13
160x600 placeholder
resx18 Member Level  Wednesday, 12/11/19 12:22:01 PM
Re: Papa Bear post# 8
Post # of 37 
Nice news ! $KLFE

DOYLESTOWN, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the filing of a new U.S. Patent for its proprietary and novel CBD-like molecules to treat radiation dermatitis (RD) and other skin disorders.

The major side effect of RD is skin tissue damage also known as radiodermatitis which occurs in 95% of cancer patients receiving radiation therapy (RT). While acute inflammation is observed within hours of RT, this painful and common side effect develops over weeks and its severity with time progresses to erythema, dry or wet desquamation or ulceration. Currently, no single agent has been shown to completely alleviate the radiation dermatitis side effect. Current therapies that focus on the symptoms include corticosteroid cream, antibiotics, zinc and amifostine. Because of the widespread incidence and the paucity of completely effective therapies, there is an urgent need for new and effective therapies, particularly those employing small molecules that are directed on regulating free radicals and decreasing the concentration of mediators of inflammation which are largely cytokines.

A December 2017 report by Transparency Market Research projects the radiodermatitis market to reach $420 million by 2024.

“We are currently in the midst of and performing pre-clinical research on our lead compound covered under our patent filing. We believe we have a solid candidate to bring forth to bridge the gap from current therapies that focus on symptoms to a therapeutic agent and more readily alleviate the RT side effect,” said Dean Petkanas, CEO of Kannalife. “Again, our early research efforts into the limitations and potential for CBD has brought us to creating a new class of patented CBD-like compounds such as KLS-13019. We believe as is the case in KLS-13019, the new compounds now subject to our patent 62/934,861 patent filing have significant advantages to CBD in treating oxidative stress-related diseases.”

“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”


Warren Buffett
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist